Italy's Angelini Pharma teams up with JCR on blood-brain barrier deal
Angelini Pharma plans to pay Japanese pharma JCR Pharmaceuticals more than $500 million as part of a research collaboration that focuses on the blood-brain barrier.
The CNS-focused pharma company, part of the Italian conglomerate Angelini Industries, put out word Thursday about the new development and commercialization agreement, which aims to develop new treatments for epilepsy.
As part of the development and commercialization agreement, Angelini will reimburse JCR for research expenses and pay an undisclosed upfront payment — along with $505.5 million in milestones, plus royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.